StreetAlpha.app
Home › Stocks › STOK

Stoke Therapeutics, Inc. (STOK)

Healthcare
$26.81
▼ −0.45%
LAST CLOSE · NOV 20

Stoke Therapeutics develops RNA-based medicines, led by zorevunersen, a candidate in clinical testing for Dravet syndrome, a severe genetic epilepsy. It last closed at $26.81 on Nov 20, down 0.45% on the day. The next earnings report for STOK is expected around Mon, Jan 11, 2027. For the quarter ended Sep 2026, STOK reported EPS of -$1.08 on revenue of $11.3M, with revenue up 5.9% from a year ago. Over its last 8 reports the stock moved an average of 7.8% the session after earnings. Over the last 12 months STOK insiders bought $0 of stock on the open market and sold $7.9M, according to SEC Form 4 filings.

AI Auto Pilots
Is STOK in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold STOK.

Key Stats

Last 12 months
Results
Revenue
$28.2M
−86.3% vs a year ago
Net income
−$243.2M
−699.5% vs a year ago
EPS (diluted)
−$3.78
−655.9% vs a year ago
Free cash flow
−$215.7M
−764.7% margin
Valuation
Market cap
$1.8B
65.4M shares
P/E
–
No P/E while losing money
Price to sales
62.2
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$107.3M
At Sep 30
Shareholder equity
$352.6M
Shares outstanding
65.4M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2022: $12.4M$12.4MFY2022FY2023: $8.8M$8.8MFY2023FY2024: $36.6M$36.6MFY2024FY2025: $184.4M$184.4MFY2025

From STOK's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 3). Last 12 months adds up the four latest quarters.

Next report
Jan 11
Estimated date · Time not announced
Reported EPS
-$1.08
Quarter ended Sep 2026
Year ago EPS
-$0.65
Same quarter last year
Revenue
$11.3M
+5.9% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.17Dec '24Mar 2025: $1.90Mar '25Jun 2025: -$0.40Jun '25Sep 2025: -$0.65Sep '25Dec 2025: -$0.97Dec '25Mar 2026: -$0.79Mar '26Jun 2026: -$0.93Jun '26Sep 2026: -$1.08Sep '26Latest -$1.08
Revenue by quarter
Dec 2024: $22.6MDec '24Mar 2025: $158.6MMar '25Jun 2025: $13.8MJun '25Sep 2025: $10.6MSep '25Dec 2025: $1.4MDec '25Mar 2026: $6.2MMar '26Jun 2026: $9.3MJun '26Sep 2026: $11.3MSep '26Latest $11.3M
How STOK moved after its last 8 reports
Average move the session after a report ±7.8%
Oct 29, 2026After the close−0.2%
Aug 3, 2026After the close+7.1%
May 7, 2026After the close+0.3%
Jan 12, 2026Time not announced−10.4%
Nov 4, 2025After the close−9.9%
Aug 12, 2025After the close+25.0%
May 13, 2025Time not announced−7.6%
Mar 18, 2025Time not announced−1.4%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on STOKStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on STOK
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on STOK

Technical Analysis

STOK · as of the Nov 20 close · updated each morning
Bounce inside a longer downtrend

The stock is 1% above its 20 day and 2% above its 50 day average. It is 14% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 52). The nearest support is the 20 day average at $26.66, and the nearest resistance the Pivot at $26.84.

Short trendBullish
Long trendBearish
MomentumImproving
StretchNormal
VolatilityNormal, 4.9%/day
Key levels
$40.2252 week high+50.0%
$30.67200 day average+14.4%
$28.54100 day average+6.5%
$27.75Pivot R1+3.5%
$27.22Swing high (Oct 20)+1.5%
$26.84Pivot+0.1%
$26.81Last close
$26.6620 day average−0.6%
$26.1650 day average−2.4%
$25.91Pivot S1−3.4%
$25.65Swing low (Nov 13)−4.3%
$22.0552 week low−17.8%
Indicators
RSI (14)52.07Middle of its rangeNeutral
MACD0.18Above its signal lineBullish
Stochastic41.6Middle of its rangeNeutral
ADX (14)15.1No clear trend
Williams %R-58.4Oversold below −80, overbought above −20Neutral
CCI (20)31.7Oversold below −100, overbought above 100Neutral
Rate of change+1.0%Change over 10 sessionsBullish
ATR (14)$1.32Typical daily range, 4.9% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Below
MA 200Below
What happened before, for STOK

What happened before

See how STOK did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow STOK usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How STOK has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for STOKHow many large options trades hit STOK, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

STOK Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼80 buying vs 100 selling
  • ▼Held by funds -5.7 pts
  • ▼Funds holding -13
  • ▲Superinvestors: 2 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding185198−6.6%
In funds' top 1034−25.0%
Held by funds112.6%118.3%−5.7 pts
New / increased15 / 6528 / 76−23.1%
Reduced / sold out72 / 2857 / 28+17.6%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See STOK institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

STOK Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$7.9M31 sales · 8 insiders
81% of the selling was under pre-arranged trading plans.
2025-12 sold $1.8M2026-03 sold $3.1M2026-04 sold $60K2026-05 sold $74K2026-06 sold $99K2026-07 sold $236K2026-08 sold $855K2026-09 sold $170K2026-10 sold $44K2026-11 sold $190KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 2Barry TichoChief Medical OfficerSale plan7,195$26.39$190K
Oct 2Jonathan AllanGeneral Counsel & Corp SecSale plan627$26.33$17K
Oct 1Barry TichoChief Medical OfficerSale plan1,051$26.16$27K
Sep 1Barry TichoChief Medical OfficerSale plan5,545$30.67$170K
Aug 18Edward M. Kaye MDDirectorSale12,567$32.03$403K
Aug 18Barry TichoChief Medical OfficerSale4,767$32.03$153K
Every insider buy and sale for STOK over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See STOK insider trades →

From SEC Form 4 filings by STOK's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether STOK is in one of them and how their past STOK trades turned out.

STOK in the AI portfolios
Loading…

STOK News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered STOK in an article yet. Here's the latest on the wider market.

STOK in the news

About Stoke Therapeutics

Stoke Therapeutics is a biopharmaceutical company based in Bedford, Massachusetts, that develops RNA-based medicines. Its TANGO approach uses antisense oligonucleotides to raise levels of specific proteins in diseases caused by a shortage of one working gene copy. Its lead candidate, zorevunersen, is in late stage clinical testing for Dravet syndrome, a severe genetic epilepsy. The company focuses on diseases of the brain and eye and plans to sell its medicines to patients and healthcare providers in the United States, Canada and Mexico.

Headquarters
Bedford, MA